SEGMENTED INFORMATION (Details) - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
SEGMENTED INFORMATION
Interest income	$ 23,568	$ 28,983
Fair value gain on investments in equity securities	4,514	84,785
Gain on disposal of investments in equity securities	0	6,181
Reversal of expected credit losses	25,153	31,752
Others	29,251	41,200
OTHER INCOME	91,420	201,847
Sales and marketing	(540,695)	(153,871)
Research and development	(12,139)	(11,475)
General and administrative	(391,876)	(315,794)
Fair value loss on investments in equity securities	(68,497)	(44,297)
Provision for expected credit losses	(40,124)	(120,469)
TOTAL OPERATING EXPENSES	(1,053,331)	(645,906)
LOSS FROM OPERATIONS	(618,418)	(79,028)
FINANCE COSTS	(4,909)	(4,661)
LOSS BEFORE TAX	(623,327)	(83,689)
Total tax (expense)/credit	0	(20,068)
Net Income (Loss) Available to Common Stockholders, Basic	(623,327)	(103,757)
REVENUE	2,137,075	2,381,851
COST OF REVENUE (including $nil and $77,214 of cost of revenue from related parties for the periods ended March 31, 2025 and 2024, respectively)	(1,793,582)	(2,016,820)
GROSS PROFIT	343,493	365,031
Dividend income	8,934	8,946
Provision For Genomic Screening Services [Member]
SEGMENTED INFORMATION
Interest income	20,002	23,783
Fair value gain on investments in equity securities	0	0
Gain on disposal of investments in equity securities		0
Reversal of expected credit losses	0	0
Others	3,893	14,911
OTHER INCOME	23,895	38,694
Sales and marketing	(27,640)	(31,105)
Research and development	(12,139)	(11,475)
General and administrative	(56,006)	(38,275)
Fair value loss on investments in equity securities	0	0
Provision for expected credit losses	0	0
TOTAL OPERATING EXPENSES	(95,785)	(80,855)
LOSS FROM OPERATIONS	(70,228)	(41,248)
FINANCE COSTS	(3,364)	(1,950)
LOSS BEFORE TAX	(73,592)	(43,198)
Total tax (expense)/credit		0
Net Income (Loss) Available to Common Stockholders, Basic	(73,592)	(43,198)
REVENUE	3,068	3,165
COST OF REVENUE (including $nil and $77,214 of cost of revenue from related parties for the periods ended March 31, 2025 and 2024, respectively)	(1,406)	(2,252)
GROSS PROFIT	1,662	913
Dividend income	0	0
Investment Holding [Member]
SEGMENTED INFORMATION
Interest income	0	0
Fair value gain on investments in equity securities	0	0
Gain on disposal of investments in equity securities		0
Reversal of expected credit losses	0	0
Others	0	0
OTHER INCOME	0	0
Sales and marketing	(4,065)	(2,324)
Research and development	0	0
General and administrative	(210,737)	(147,098)
Fair value loss on investments in equity securities	0	0
Provision for expected credit losses	0	0
TOTAL OPERATING EXPENSES	(214,802)	(149,422)
LOSS FROM OPERATIONS	(214,802)	(149,422)
FINANCE COSTS	(43)	(24)
LOSS BEFORE TAX	(214,845)	(149,446)
Total tax (expense)/credit		0
Net Income (Loss) Available to Common Stockholders, Basic	(214,845)	(149,446)
REVENUE	0	0
COST OF REVENUE (including $nil and $77,214 of cost of revenue from related parties for the periods ended March 31, 2025 and 2024, respectively)	0	0
GROSS PROFIT	0	0
Dividend income	0	0
Trading Of Industrial Chemicals [Member]
SEGMENTED INFORMATION
Interest income	3,566	5,200
Fair value gain on investments in equity securities	4,514	84,785
Gain on disposal of investments in equity securities		6,181
Reversal of expected credit losses	25,153	31,752
Others	25,358	26,289
OTHER INCOME	67,525	163,153
Sales and marketing	(508,990)	(120,442)
Research and development	0	0
General and administrative	(125,133)	(130,421)
Fair value loss on investments in equity securities	(68,497)	(44,297)
Provision for expected credit losses	(40,124)	(120,469)
TOTAL OPERATING EXPENSES	(742,744)	(415,629)
LOSS FROM OPERATIONS	(333,388)	111,642
FINANCE COSTS	(1,502)	(2,687)
LOSS BEFORE TAX	(334,890)	108,955
Total tax (expense)/credit		(20,068)
Net Income (Loss) Available to Common Stockholders, Basic	(334,890)	88,887
REVENUE	2,134,007	2,378,686
COST OF REVENUE (including $nil and $77,214 of cost of revenue from related parties for the periods ended March 31, 2025 and 2024, respectively)	(1,792,176)	(2,014,568)
GROSS PROFIT	341,831	364,118
Dividend income	$ 8,934	$ 8,946